OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial
Magdalena E. Sobieszczyk, Sharon Mannheimer, Carmen A. Paez, et al.
The Lancet HIV (2023) Vol. 10, Iss. 10, pp. e653-e662
Open Access | Times Cited: 18
Magdalena E. Sobieszczyk, Sharon Mannheimer, Carmen A. Paez, et al.
The Lancet HIV (2023) Vol. 10, Iss. 10, pp. e653-e662
Open Access | Times Cited: 18
Showing 18 citing articles:
HIV diagnosis during acute infection: implications of long-acting preexposure prophylaxis and other evolving challenges
Tamara Elliott, Daniel Bradshaw, Sarah Fidler
Current Opinion in HIV and AIDS (2025)
Closed Access
Tamara Elliott, Daniel Bradshaw, Sarah Fidler
Current Opinion in HIV and AIDS (2025)
Closed Access
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
Tariro Dianah Chawana, Stephen R. Walsh, Lynda Stranix‐Chibanda, et al.
BMC Immunology (2025) Vol. 26, Iss. 1
Open Access
Tariro Dianah Chawana, Stephen R. Walsh, Lynda Stranix‐Chibanda, et al.
BMC Immunology (2025) Vol. 26, Iss. 1
Open Access
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV
Bryan T. Mayer, Lily Zhang, Allan C. deCamp, et al.
Pharmaceutics (2024) Vol. 16, Iss. 5, pp. 594-594
Open Access | Times Cited: 5
Bryan T. Mayer, Lily Zhang, Allan C. deCamp, et al.
Pharmaceutics (2024) Vol. 16, Iss. 5, pp. 594-594
Open Access | Times Cited: 5
Structural development of the HIV-1 apex-directed PGT145-PGDM1400 antibody lineage
Rosemarie D. Mason, Baoshan Zhang, Nicholas C. Morano, et al.
Cell Reports (2025) Vol. 44, Iss. 1, pp. 115223-115223
Open Access
Rosemarie D. Mason, Baoshan Zhang, Nicholas C. Morano, et al.
Cell Reports (2025) Vol. 44, Iss. 1, pp. 115223-115223
Open Access
Antibody prophylaxis may mask subclinical SIV infections in macaques
Christopher A. Gonelli, Hannah A. D. King, Sung‐Youl Ko, et al.
Nature (2025)
Open Access
Christopher A. Gonelli, Hannah A. D. King, Sung‐Youl Ko, et al.
Nature (2025)
Open Access
Subcutaneous Liposomal Delivery Improves Monoclonal Antibody Pharmacokinetics in vivo
Maryam Karimi, Arash Aslanabadi, Ben Atkinson, et al.
Acta Biomaterialia (2025)
Closed Access
Maryam Karimi, Arash Aslanabadi, Ben Atkinson, et al.
Acta Biomaterialia (2025)
Closed Access
Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives
Sharana Mahomed
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 4
Sharana Mahomed
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 4
Is HIV epidemic control by 2030 realistic?
Chris Beyrer, Georgia D Tomaras, Huub C Gelderblom, et al.
The Lancet HIV (2024) Vol. 11, Iss. 7, pp. e489-e494
Closed Access | Times Cited: 4
Chris Beyrer, Georgia D Tomaras, Huub C Gelderblom, et al.
The Lancet HIV (2024) Vol. 11, Iss. 7, pp. e489-e494
Closed Access | Times Cited: 4
A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087)
Stephen R. Walsh, Cynthia L. Gay, Shelly Karuna, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Stephen R. Walsh, Cynthia L. Gay, Shelly Karuna, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention
Jannifer Jasmin Thavarajah, Bo Langhoff Hønge, Christian Wejse
Viruses (2024) Vol. 16, Iss. 6, pp. 911-911
Open Access | Times Cited: 2
Jannifer Jasmin Thavarajah, Bo Langhoff Hønge, Christian Wejse
Viruses (2024) Vol. 16, Iss. 6, pp. 911-911
Open Access | Times Cited: 2
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial
Stephen R. Walsh, Cynthia L. Gay, Shelly Karuna, et al.
PLoS Medicine (2024) Vol. 21, Iss. 6, pp. e1004329-e1004329
Open Access | Times Cited: 2
Stephen R. Walsh, Cynthia L. Gay, Shelly Karuna, et al.
PLoS Medicine (2024) Vol. 21, Iss. 6, pp. e1004329-e1004329
Open Access | Times Cited: 2
Advancing bnAb combinations for HIV prevention
Henning Gruell, Philipp Schommers
The Lancet HIV (2023) Vol. 10, Iss. 10, pp. e625-e626
Closed Access | Times Cited: 5
Henning Gruell, Philipp Schommers
The Lancet HIV (2023) Vol. 10, Iss. 10, pp. e625-e626
Closed Access | Times Cited: 5
New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs
Maria Marra, Alessia Catalano, Maria Stefania Sinicropi, et al.
Viruses (2024) Vol. 16, Iss. 9, pp. 1484-1484
Open Access | Times Cited: 1
Maria Marra, Alessia Catalano, Maria Stefania Sinicropi, et al.
Viruses (2024) Vol. 16, Iss. 9, pp. 1484-1484
Open Access | Times Cited: 1
Influence of AAV vector tropism on long-term expression and Fc-γ receptor binding of an antibody targeting SARS-CoV-2
Jannik T. Wagner, Sandra M. Müller-Schmucker, Wenjun Wang, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access
Jannik T. Wagner, Sandra M. Müller-Schmucker, Wenjun Wang, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access
The XbnAb Cohort: 304 people with broadly neutralizing antibody activity to HIV-1
Chloé Pasin, Peter Rusert, Daniel Schmidt, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
Chloé Pasin, Peter Rusert, Daniel Schmidt, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
Advances in the mathematical modeling of posttreatment control of HIV-1
Bharadwaj Vemparala, Jérémie Guedj, Narendra M. Dixit
Current Opinion in HIV and AIDS (2024) Vol. 20, Iss. 1, pp. 92-98
Closed Access
Bharadwaj Vemparala, Jérémie Guedj, Narendra M. Dixit
Current Opinion in HIV and AIDS (2024) Vol. 20, Iss. 1, pp. 92-98
Closed Access
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Srilatha Edupuganti, Christopher B. Hurt, Kathryn E. Stephenson, et al.
The Lancet HIV (2024) Vol. 12, Iss. 1, pp. e13-e25
Closed Access
Srilatha Edupuganti, Christopher B. Hurt, Kathryn E. Stephenson, et al.
The Lancet HIV (2024) Vol. 12, Iss. 1, pp. e13-e25
Closed Access
Associations between gender and solicited adverse events after passive infusion of VRC01 or placebo in HVTN 704/HPTN 085
Deborah Theodore, Moni B. Neradilek, Kevin Gillespie, et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes (2024) Vol. 98, Iss. 4, pp. 340-345
Closed Access
Deborah Theodore, Moni B. Neradilek, Kevin Gillespie, et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes (2024) Vol. 98, Iss. 4, pp. 340-345
Closed Access
